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Abstract
Background: The antibacterial effect of silver nanoparticles has resulted in their extensive application in health,
electronic, consumer, medicinal, pesticide, and home products; however, silver nanoparticles remain a controversial
area of research with respect to their toxicity in biological and ecological systems.
Results: This study tested the oral toxicity of silver nanoparticles (56 nm) over a period of 13 weeks (90 days) in
F344 rats following Organization for Economic Cooperation and Development (OECD) test guideline 408 and Good
Laboratory Practices (GLP). Five-week-old rats, weighing about 99 g for the males and 92 g for the females, were
divided into four 4 groups (10 rats in each group): vehicle control, low-dose (30 mg/kg), middle-dose (125 mg/kg),
and high-dose (500 mg/kg). After 90 days of exposure, clinical chemistry, hematology, histopathology, and silver
distribution were studied. There was a significant decrease (P < 0.05) in the body weight of male rats after 4 weeks
of exposure, although there were no significant changes in food or water consumption during the study period.
Significant dose-dependent changes were found in alkaline phosphatase and cholesterol for the male and female
rats, indicating that exposure to more than 125 mg/kg of silver nanoparticles may result in slight liver damage.
Histopathologic examination revealed a higher incidence of bile-duct hyperplasia, with or without necrosis, fibrosis,
and/or pigmentation, in treated animals. There was also a dose-dependent accumulation of silver in all tissues
examined. A gender-related difference in the accumulation of silver was noted in the kidneys, with a twofold
increase in female kidneys compared to male kidneys.
Conclusions: The target organ for the silver nanoparticles was found to be the liver in both the male and female
rats. A NOAEL (no observable adverse effect level) of 30 mg/kg and LOAEL (lowest observable adverse effect level)
of 125 mg/kg are suggested from the present study.
Background
The antibacterial activity exhibited by silver in a range
of studies [1-5] has resulted in the widespread use of sil-
ver nanoparticles in bedding, washing machines, water
purification, toothpaste, shampoo and rinse, nipples and
nursing bottles, fabrics, deodorants, filters, kitchen uten-
sils, toys, and humidifiers [6,7], where the main body or
inner surface of the product is mixed or coated with
germ-resistant nano-silver to prevent the growth of
fungi and bacteria. Despite such widespread use of sil-
ver-nanoparticle-containing products, subchronic and
chronic toxicity data on silver nanoparticles remain rare.
The lack of exposure data on silver nanoparticles in the
workplace and silver nanoparticles released from consu-
mer products or released into the environment makes it
difficult to assess the risks of using these materials. Lim-
ited data have been reported for silver nanoparticles by
inhalation and oral routes of exposure. The target
organs for silver nanoparticles by subchronic inhalation
are the lungs and liver in male and female rats [8]. This
study suggested a NOAEL (no observable adverse effect
level) of 100 μg/m
3.
A LOAEL (lowest observable adverse effect level) and
NOAEL have been reported for a 28-day oral toxicity
study using Sprague-Dawley rats to be 300 mg/kg and 30
mg/kg, respectively [9]. In this study, F344 rats were
exposed to silver nanoparticles following the Organization
for Economic Cooperation and Development (OECD)
test guideline 408 (OECD, 1998), using a 13-week
repeated-oral-dose toxicity protocol. The study was con-
ducted under OECD Good Laboratory Practices (GLP).
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Materials and methods
Silver Nanoparticles
Silver nanoparticles (CAS No. 7440-22-4) were pur-
chased from NAMATECH, Ltd. (Daejeon, Korea), and
were at least 99.98% pure. Count median diameter and
geometric standard deviation of silver nanoparticles in
0.5% aqueous carboxymethylcellulose (CMC, Sigma
USA) analyzed by transmission electron microscopy
were 56 nm and 1.46, respectively (Figure 1).
Transmission Electron Microscopy
The filters on which the silver nanoparticles in the 0.5%
CMC were filtered were coated with carbon, mounted
on an electron microscope grid (200 mesh, Veco, Eer-
beek, Holland), and visualized under a transmission
electron microscope (TEM, Hitachi 7100). The dia-
meters of 400 randomly selected particles were mea-
sured at 50,000 × magnification, and the silver particles
were analyzed using an energy-dispersive x-ray analyzer
(EDX-200, Horiba, Japan) at an accelerating voltage of
75 kV.
Animals and Conditions
Four-week-old male and female, specific-pathogen free
(SPF) Fisher 344 rats were purchased from Japan SLC
Inc. (Japan) and acclimated for 7 days before starting
the experiments. During the acclimation and experimen-
tal periods, the rats were housed in polycarbonate cages
(maximum of 3 rats per cage) in a room with controlled
Figure 1 Transmission electron micrograph of silver nanoparticles and distribution of silver nanoparticles.T h eb a ri n d i c a t e s2μm. A.
Transmission electron micrograph of silver nanoparticles. B. Energy dispersive x-ray profile (silver nanoparticles on copper grid). C. Distribution of
silver nanoparticles.
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Page 2 of 11temperature (22.2 ± 1.7°C) and humidity (48.4 ± 6.0%),
and a 12-h light/dark cycle. The rats were fed a rodent
diet (Harlan Teklad, USA) and filtered water ad libitum.
The rats were divided into 4 groups (10 rats in each
group): vehicle control (0.5% carboxymethylcellulose,
CMC), low-dose group (30 mg/kg/day), middle-dose
group (125 mg/kg/day), and high-dose group (500 mg/
kg/day). When the rats reached five weeks of age, they
were exposed to silver nanoparticles following OECD
test guideline 408 [10] by gavage for 13 weeks of
repeated oral administration (dosing volumes were 10
ml/kg). Dose levels were selected based on previous
observations in a 28-day oral toxicity study by Kim et al.
[9]. The study was conducted under OECD Good
Laboratory Practices.
Clinical Chemistry and Hematology
At the conclusion of the 13-wk experiment, the rats
were 18 wks old. Before necropsy, food was withheld for
24 h and the rats were anesthetized with CO2 gas.
Blood was then drawn from the abdominal aorta, col-
lected in heparinized vacutainers, and analyzed for ALB
(albumin), ALP (alkaline phosphatase), Ca (calcium),
CHO (cholesterol), CRE (creatinine), gamma-GT
(gamma-glutamyl transpeptidase), GLU (glucose), GOT
(glutamic oxaloacetic transaminase), GPT (glutamic
pyruvic transminase), IP (inorganic phosphorus), LDH
(lactate dehydrogenase), MG (magnesium), TP (total
protein), UA (uric acid), BUN (blood urea nitrogen),
TBIL (total bilirubin), CK (creatine phosphokinase), Na
(sodium), K (potassium), Cl (chloride), TG (triglyceride),
and A/G (ratio of albumin to globulin) using a biochem-
ical blood analyzer (Hitachi 7180, Hitachi, Japan). The
blood was also analyzed for the WBC (white blood cell
count), RBC (red blood cell count), Hb (hemoglobin
concentration), HTC (hematocrits), MCV (mean corpus-
cular volume), MCH (mean corpuscular hemoglobin),
MCHC (mean corpuscular hemoglobin concentration),
RDW (red cell distribution width), PLT (platelet count),
MPV (mean platelet volume), NE# (number of neutro-
phils), NE% (percent of neutrophils), LY# (number of
lymphocytes), LY% percent of lymphocytes), MO#
(number of monocytes), MO% (percent of monocytes),
EO# (number of eosinophils), EO% (percent of eosino-
phils), BA# (number of basophils), and BA% (percent of
basophils) using a blood cell counter (Hemavet 0950,
CDC Tech., USA).
Organ Weights and Histopathology
After collecting blood samples, the rats were killed by
cervical dislocation. Adrenal glands, bladder, testes, ovar-
ies, uterus, epididymis, seminal vesicle, heart, thymus,
thyroid gland, trachea, esophagus, tongue, prostate, lungs,
nasal cavity, kidneys, spleen, liver, pancreas, and brain
were removed carefully, weighed, and fixed in a 10%
formalin solution containing neutral phosphate-buffered
saline. Thereafter, the organs were embedded in paraffin,
stained with hematoxylin and eosin, and examined under
light microscopy.
Determination of Tissue Silver
Tissues were digested with conc. nitric acid by using a
microwave digestion system (MARS 230/60, CEM). The
concentration of silver in digested fluid was analyzed
with a flameless method using an atomic absorption
spectrophotometer equipped with a Zeeman graphite
furnace (Perkin Elmer 5100ZL, Zeeman Furnace Mod-
ule, USA) based on the NIOSH 7300 method [11]. The
concentration of silver in the tissue was expressed as
μg/g wet weight.
Statistical Analysis
Statistical analysis was performed with SPSS (Version
12). Statistical evaluation was performed by analysis of
two-tailed Student’st - t e s to ra n a l y s i so fv a r i a n c e
(ANOVA) following multiple comparison tests with
Duncan’s method. The level of statistical significance
was set at p < 0.05
Results
Animal Observation, Food Consumption, and Effect on
Body and Organ Weights
There were no significant differences in food consump-
tion and water intake between treated male and female
rats and the control group (data not shown). There
were no significant dose-related changes in the body
weight of female rats; however, there were significant
(P < 0.05) dose-related decreases in the body weight of
high-dose male rats at 4, 5, and 7 weeks of exposure at
the conclusion of the study 13 weeks, and middle-dose
male rats at 10 weeks of exposure (Figure 2). No signifi-
cant organ-weight changes were observed in either the
male or female rats after 90 days except for an increase
(P < 0.05) in the weight of the left testis for the high-
dose male rats, and for decreases (P < 0.05) in the
weight of right kidney for the low-and middle-dose
female rats (Tables 1 and 2).
Effects on Clinical Chemistry and Hematology
There appeared to be increase ALP for male rats in the
middle and high-dose groups statistically not significant
(Table 3). However, there was a significant increase
(P < 0.01) in alkaline phosphatase (ALP) for female rats in
the high-dose groups (Table 4). A significant increase
(P < 0.01) in cholesterol was also found in the middle
and high-dose male rats and the high-dose female rats
(Table 3 and 4). A significant increase (P < 0.05) in
total bilirubin was noted in the middle-dose male rats
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Page 3 of 11Figure 2 Body weight changes during 90-day oral administration of silver nanoparticles. A. Male. a Significant difference vs. control, p <
0.05. (10 weeks). b Significant difference vs. control, p < 0.05. (4, 5, 7~13 weeks). B. Female.
Table 1 Relative organ weights for male rats after 90-day
oral administration of silver nanoparticles (mean ± S.D.,
n≥9)
Dose (mg/Kg)
0 30 125 500
Testis (Left) 0.47 ± 0.02 0.48 ± 0.03 0.49 ± 0.02 0.51 ±
0.01*
Testis (Right) 0.47 ± 0.02 0.48 ± 0.02 0.48 ± 0.02 0.49 ± 0.02
Spleen 0.21 ± 0.03 0.21 ± 0.01 0.22 ± 0.01 0.20 ± 0.02
Liver 2.96 ± 0.10 2.91 ± 0.16 2.92 ± 0.09 2.87 ± 0.11
Pituitary gland 0.002 ±
0.001
0.003 ±
0.001
0.005 ±
0.006
0.004 ±
0.003
Adrenal gland
(Left)
0.011 ±
0.006
0.007 ±
0.002
0.008 ±
0.001
0.009 ±
0.003
Adrenal gland
(Right)
0.008 ±
0.001
0.007 ±
0.001
0.008 ±
0.001
0.009 ±
0.002
Prostate 0.13 ± 0.06 0.16 ± 0.05 0.15 ± 0.04 0.16 ± 0.05
Lungs 0.42 ± 0.02 0.41 ± 0.04 0.42 ± 0.03 0.43 ± 0.03
Brain 0.62 ± 0.02 0.61 ± 0.03 0.62 ± 0.02 0.63 ± 0.02
Heart 0.27 ± 0.02 0.26 ± 0.02 0.27 ± 0.01 0.26 ± 0.02
Thymus 0.10 ± 0.02 0.10 ± 0.02 0.11 ± 0.02 0.10 ± 0.02
Kidney (Left) 0.28 ± 0.01 0.28 ± 0.02 0.29 ± 0.01 0.28 ± 0.01
Kidney (Right) 0.29 ± 0.02 0.28 ± 0.02 0.29 ± 0.01 0.29 ± 0.01
*Significant difference vs. control, p < 0.05
Table 2 Relative organ weights for female rats after 90-
day oral administration of silver nanoparticles (mean ± S.
D., n≥9)
Dose (mg/Kg)
0 30 125 500
Ovary (Left) 0.027 ±
0.004
0.026 ±
0.005
0.023 ±
0.003
0.024 ±
0.007
Ovary (Right) 0.072 ±
0.134
0.025 ±
0.006
0.026 ±
0.003
0.028 ±
0.005
Spleen 0.22 ± 0.02 0.21 ± 0.01 0.21 ± 0.01 0.21 ± 0.02
Liver 2.67 ± 0.18 2.61 ± 0.07 2.53 ± 0.12 2.62 ± 0.17
Pituitary gland 0.007 ±
0.002
0.006 ±
0.002
0.006 ±
0.001
0.007 ±
0.002
Adrenal gland
(Left)
0.015 ±
0.003
0.014 ±
0.002
0.014 ±
0.001
0.015 ±
0.003
Adrenal gland
(Right)
0.014 ±
0.001
0.014 ±
0.002
0.014 ±
0.002
0.015 ±
0.001
Uterus 0.233 ±
0.044
0.257 ±
0.090
0.216 ±
0.040
0.195 ±
0.040
Lungs 0.54 ± 0.06 0.55 ± 0.04 0.50 ± 0.05 0.54 ± 0.05
Brain 0.99 ± 0.05 0.98 ± 0.05 0.99 ± 0.06 1.00 ± 0.05
Heart 0.32 ± 0.02 0.32 ± 0.02 0.31 ± 0.02 0.32 ± 0.03
Thymus 0.14 ± 0.02 0.13 ± 0.02 0.13 ± 0.02 0.15 ± 0.02
Kidney (Left) 0.31 ± 0.02 0.30 ± 0.02 0.30 ± 0.01 0.30 ± 0.02
Kidney (Right) 0.31 ± 0.02 0.29 ±
0.01*
0.30 ±
0.01*
0.30 ± 0.02
*Significant difference vs. control, p < 0.05
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and inorganic phosphorus was found in the middle and
high-dose female rats (Table 4). No significant changes in
the hematological parameters were noted except for a sig-
nificant increase (P < 0.05) in monocytes in the high-dose
female rats (Table 5 and 6). The reticulocyte count for the
low-dose female rats decreased significantly (p < 0.05)
when compared with the control group (Table 7). Coagu-
lation time in terms of the active partial thromboplastin
time (APTT) and prothrombin time (PT) did not show
any significant changes when compared with the control
group (Figure 3).
Histopathologic Examination
In the liver, minimal bile-duct hyperplasia was identified
in 4/10, 7/10, 8/10, and 6/10 of control, low, middle, and
h i g h - d o s em a l er a t s ,r e s p e c tively (Table 8, Figure 4C).
The higher incidence of bile-duct hyperplasia in treated
male rats suggests a minimal effect due to silver nanopar-
ticles in the treated groups. Minimal bile-duct hyperplasia
was also present in 3/10, 7/10, 8/10, and 7/10 of the con-
trol, low, middle, and high-dose female rats, respectively
(Table 9). Focal, multifocal, or lobular necrosis was noted
in 0/10, 4/10, 5/10, and 4/10 of the control, low, middle,
and high-dose male rats, respectively, and 0/10, 2/10, 2/
Table 3 Serum values for male rats after 90-day oral
administration of silver nanoparticles (mean ± S.D.)
Dose (mg/Kg)
0 (n = 10) 30 (n = 10) 125 (n = 10) 500 (n = 10)
ALB 2.92 ± 0.26 2.82 ± 0.13 2.79 ± 0.10 2.86 ± 0.10
ALP 291.60 ± 35.40 279.50 ± 48.78 306.40 ± 35.16 343.80 ± 65.67
CA 10.93 ± 0.59 10.77 ± 0.67 10.49 ± 0.22 10.60 ± 0.24
CHO 88.50 ± 8.45 94.80 ± 7.54 98.30 ± 5.46** 106.00 ±
6.38**
CRE 0.91 ± 0.10 0.86 ± 0.11 0.85 ± 0.05 0.83 ± 0.15
GGT 0.40 ± 0.52 0.10 ± 0.32 0.40 ± 0.52 0.50 ± 0.53
GLU 168.20 ± 24.36 193.50 ± 42.15 165.40 ± 17.66 177.70 ± 20.89
AST 105.00 ± 27.01 97.10 ± 22.71 85.00 ± 12.35 98.20 ± 35.64
ALT 72.10 ± 5.17 77.20 ± 8.39 68.70 ± 4.64 71.40 ± 20.03
LDH 1230.80 ±
1351.96
784.80 ±
675.03
598.70 ±
351.37
644.20 ±
400.41
MG 2.27 ± 0.33 2.36 ± 0.62 2.06 ± 0.10 2.19 ± 0.09
TP 6.61 ± 0.21 6.51 ± 0.23 6.42 ± 0.19 6.56 ± 0.21
UA 1.19 ± 0.73 1.33 ± 1.21 0.79 ± 0.29 0.76 ± 0.22
BUN 22.14 ± 1.68 21.60 ± 2.59 22.47 ± 1.89 22.76 ± 2.93
T-
BIL
0.009 ± 0.013 0.006 ± 0.008 0.024 ± 0.017* 0.013 ± 0.014
IP 6.99 ± 0.82 6.98 ± 1.06 6.40 ± 0.51 6.59 ± 0.56
TG 140.20 ± 42.35 156.30 ± 49.69 161.40 ± 44.60 140.40 ± 47.28
CPK 554.10 ± 598.27 342.60 ±
267.05
269.10 ±
128.28
273.50 ±
130.37
Na 139.50 ± 1.18 142.40 ± 6.80 140.40 ± 0.70 141.20 ± 0.79
K 4.48 ± 0.98 4.36 ± 1.01 3.95 ± 0.78 3.99 ± 0.44
Cl 100.80 ± 1.40 102.30 ± 3.95 101.70 ± 0.67 101.40 ± 1.35
Note. ALB(g/dL), Albumin; ALP(IU/L), Alkaline phosphatase; CA(mg/dL),
Calcium; CHO(mg/dL), Total cholesterol; CRE(mg/dL), Creatinine; GGT(IU/L),
Gamma glutamyl transpeptidase; GLU(mg/dL), Glucose; AST(IU/L), Aspartate
aminotransferase; ALT(IU/L), Alanine aminotransferase; LDH(IU/L), Lactate
dehydrogenase; MG(mg/dL), Magnesium; TP(g/dL), Total protein; UA(mg/dL),
Uric acid; BUN(mg/dL), Blood urea nitrogen; T-BIL(mg/dL), Total bilirubin; IP
(mg/dL), Inorganic phosphorus; TG(mg/dL), Triglyceride; CPK(U/L), Creatine
phosphokinase; Na(mmol/L), Sodium; K(mmol/L), Potassium; Cl(mmol/L),
Chloride.
**Significant difference vs. control, p < 0.01
*Significant difference vs. control, p < 0.05
Table 4 Serum values for female rats after 90-day oral
administration of silver nanoparticles (mean ± S.D.)
Dose (mg/Kg)
0 (n = 10) 30 (n = 9) 125 (n = 10) 500 (n = 10)
ALB 2.78 ± 0.08 2.73 ± 0.10 2.75 ± 0.24 2.63 ± 0.09
ALP 237.50 ±
29.05
241.22 ± 22.12 253.50 ±
25.42
314.80 ±
42.13**
CA 10.42 ± 0.60 10.11 ± 0.26 10.08 ± 0.30 9.98 ± 0.27
CHO 107.50 ± 7.35 115.11 ± 12.36 116.30 ± 6.95 126.70 ±
12.39**
CRE 0.85 ± 0.16 0.96 ± 0.15 0.91 ± 0.10 0.90 ± 0.13
GGT 0.80 ± 0.42 1.11 ± 0.78 0.90 ± 0.57 0.80 ± 0.63
GLU 148.70 ±
20.09
146.33 ± 14.53 151.20 ±
16.48
151.30 ± 20.19
AST 94.80 ± 11.98 84.22 ± 23.82 84.20 ± 6.89 94.80 ± 38.14
ALT 67.70 ± 6.00 59.78 ± 10.57 61.10 ± 5.15 70.90 ± 22.00
LDH 722.00 ±
480.71
705.33 ± 612.27 496.90 ±
303.14
516.90 ±
245.26
MG 2.44 ± 0.17 2.30 ± 0.24 2.17 ± 0.08** 2.18 ± 0.15**
TP 6.30 ± 0.17 6.14 ± 0.22 6.08 ± 0.14* 6.03 ± 0.23*
UA 1.12 ± 0.39 0.97 ± 0.31 0.86 ± 0.19 0.87 ± 0.12
BUN 23.61 ± 2.57 22.26 ± 2.52 21.71 ± 1.94 23.03 ± 1.64
T-
BIL
0.014 ± 0.008 0.022 ± 0.018 0.020 ± 0.018 0.019 ± 0.014
IP 6.50 ± 1.17 6.19 ± 0.99 5.43 ± 0.73* 5.32 ± 0.60*
TG 48.30 ± 24.07 55.22 ± 30.67 45.80 ± 19.99 50.30 ± 24.38
CPK 375.20 ±
290.40
1004.67 ±
2174.69
231.50 ±
124.83
245.70 ±
106.73
Na 140.10 ± 1.45 140.22 ± 0.67 141.40 ± 5.21 141.00 ± 1.05
K 4.02 ± 1.15 3.62 ± 0.73 3.40 ± 0.17 3.37 ± 0.26
Cl 102.20 ± 0.79 102.44 ± 1.13 103.60 ± 3.13 103.20 ± 1.69
Note. ALB(g/dL), Albumin; ALP(IU/L), Alkaline phosphatase; CA(mg/dL),
Calcium; CHO(mg/dL), Total cholesterol; CRE(mg/dL), Creatinine; GGT(IU/L),
Gamma glutamyl transpeptidase; GLU(mg/dL), Glucose; AST(IU/L), Aspartate
aminotransferase; ALT(IU/L), Alanine aminotransferase; LDH(IU/L), Lactate
dehydrogenase; MG(mg/dL), Magnesium; TP(g/dL), Total protein; UA(mg/dL),
Uric acid; BUN(mg/dL), Blood urea nitrogen; T-BIL(mg/dL), Total bilirubin; IP
(mg/dL), Inorganic phosphorus; TG(mg/dL), Triglyceride; CPK(U/L), Creatine
phosphokinase; Na(mmol/L), Sodium; K(mmol/L), Potassium; Cl(mmol/L),
Chloride.
*Significant difference vs. control, p < 0.05
**Significant difference vs. control, p < 0.01
Kim et al. Particle and Fibre Toxicology 2010, 7:20
http://www.particleandfibretoxicology.com/content/7/1/20
Page 5 of 1110, and 2/10 of the control, low, middle, and high-dose
female rats, respectively (Table 8 and 9, Figure 4B and
4D). The higher incidence of bile-duct hyperplasia, with
or without necrosis, fibrosis, and/or pigmentation, in the
treated animals also suggests a treatment-related effect.
Although there appeared to be a slight increase of mini-
mal tubular basophilia in the kidneys of high-dose male
rats, these changes were not statistically significant and
thus not considered to be test article exposure related.
Tubular basophilia were also more prevalent in the male
rats compared to the female rats (Table 8). Minimum or
mild renal unilateral or bilateral mineralization was
observed in 5/10, 8/10, 7/10, and 9/10 of the control,
low, middle, and high-dose female rats, respectively, indi-
cating a treatment-related effect.
Histopathologic examination of lung tissue did not
show any treatment-related effects.
In the intestines, pigmentation of villi was observed in
0/10, 0/10, 8/10, and 8/10 of the control, low, middle,
and high-dose male rats, respectively (Table 8). This
dose-dependent increase in the pigmentation of the villi
indicated an apparent treatment-related effect (Figure
5). In contrast, there was a slight treatment-related
increase in pigmentation of intestinal villi in female rats
(Table 9).
Silver Distribution in Tissues
There was a statistically significant (P < 0.01) dose-
dependent increase in the silver concentration of all the
tissue samples from the groups exposed to silver nano-
particles in this study (Table 10). In addition, a two-fold
higher accumulation of silver in the kidneys of female
rats when compared with the male rats occurred across
all the dose groups indicating a marked gender-depen-
dent distribution.
Discussion
Silver nanoparticles are widely used as bactericidal
agents in consumer products, but their potential effects
in humans remain poorly understood. Silver at doses
below levels that cause argyria or argyriosis are generally
considered to be relatively non-toxic [12]. Wijnhoven
et al. have hypothesized that the toxic effects of silver
Table 5 Hematological values for male rats after 90-day
oral administration of silver nanoparticles (mean ± SD)
Dose (mg/Kg)
0 (n = 9) 30 (n = 9) 125 (n = 10) 500 (n = 10)
WBC 8.33 ± 1.25 8.22 ± 1.44 8.17 ± 1.28 8.21 ± 1.07
RBC 8.98 ± 0.32 9.13 ± 0.66 8.88 ± 0.24 9.07 ± 0.35
Hb 16.67 ± 0.40 16.76 ± 1.10 16.47 ± 0.53 16.93 ± 0.68
HCT 36.96 ± 1.41 37.80 ± 2.90 36.97 ± 1.46 37.84 ± 2.12
MCV 41.17 ± 0.58 41.38 ± 0.72 41.62 ± 0.77 41.72 ± 0.92
MCH 18.58 ± 0.34 18.34 ± 0.40 18.55 ± 0.58 18.67 ± 0.37
MCHC 45.13 ± 1.08 44.38 ± 1.31 44.59 ± 1.69 44.79 ± 1.25
RDW 17.98 ± 0.78 17.83 ± 0.68 17.83 ± 1.04 18.10 ± 0.86
PLT 738.22 ±
53.33
731.56 ±
105.79
725.40 ±
45.43
718.50 ±
72.05
MPV 6.86 ± 0.29 6.84 ± 0.19 6.83 ± 0.27 6.64 ± 0.28
NEU 26.13 ± 3.30 26.72 ± 3.14 26.76 ± 4.14 27.12 ± 2.62
LYO 69.77 ± 3.39 68.21 ± 3.45 68.93 ± 5.30 69.34 ± 3.13
MONO 3.78 ± 0.80 4.57 ± 1.12 3.98 ± 1.19 3.35 ± 0.80
EOS 0.25 ± 0.40 0.39 ± 0.50 0.25 ± 0.21 0.15 ± 0.08
BASO 0.08 ± 0.14 0.12 ± 0.22 0.09 ± 0.08 0.04 ± 0.03
Note. WBC(K/μL), White blood cells; RBC(M/μL), Red blood cells; Hb(g/dL),
Hemoglobin; HCT(%), Hematocrits; MCV(fl), Mean corpuscular volume; MCH
(pg), Mean corpuscular hemoglobin; MCHC(g/dL), Mean corpuscular
hemoglobin concentration; RDW(%), Red cell distribution width; PLT(K/μL),
Platelets; MPV(fl), Mean platelet volume; NEU(%), Neutrophils; LYO(%),
Lymphocytes; MONO(%), Monocytes; EOS(%), Eosinophils; BASO(%), Basophils.
Table 6 Hematological values for female rats after 90-day
oral administration of silver nanoparticles (mean ± SD).
Dose (mg/Kg)
0 (n = 8) 30 (n = 10) 125 (n = 10) 500 (n = 9)
WBC 5.46 ± 1.36 5.42 ± 0.81 5.11 ± 0.67 5.90 ± 0.97
RBC 8.46 ± 0.22 8.41 ± 0.34 8.19 ± 0.32 8.28 ± 0.24
Hb 16.24 ± 0.81 16.16 ± 0.75 15.82 ± 1.02 16.14 ± 0.85
HCT 34.45 ± 2.50 34.40 ± 1.80 34.33 ± 1.82 34.51 ± 2.13
MCV 40.70 ± 1.96 40.91 ± 1.62 41.95 ± 1.81 41.71 ± 2.45
MCH 19.20 ± 0.56 19.24 ± 0.81 19.34 ± 1.36 19.50 ± 0.96
MCHC 47.21 ± 1.80 47.02 ± 1.63 46.09 ± 1.96 46.84 ± 2.41
RDW 19.33 ± 2.44 19.18 ± 2.62 18.85 ± 2.55 19.04 ± 2.46
PLT 765.75 ±
110.30
718.30 ±
68.56
712.70 ±
55.93
688.89 ±
34.71
MPV 6.56 ± 0.71 6.74 ± 0.21 6.95 ± 0.28 6.70 ± 0.22
NEU 24.93 ± 2.88 27.37 ± 3.70 26.32 ± 6.70 24.06 ± 3.49
LYO 71.48 ± 3.83 68.32 ± 4.60 69.59 ± 7.53 71.22 ± 3.83
MONO 3.00 ± 1.17 3.85 ± 1.13 3.65 ± 0.79 4.54 ± 0.60*
EOS 0.42 ± 0.52 0.36 ± 0.17 0.39 ± 0.37 0.18 ± 0.15
BASO 0.17 ± 0.25 0.11 ± 0.09 0.15 ± 0.19 0.01 ± 0.02
Note. WBC(K/μL), White blood cells; RBC(M/μL), Red blood cells; Hb(g/dL),
Hemoglobin; HCT(%), Hematocrits; MCV(fl), Mean corpuscular volume; MCH
(pg), Mean corpuscular hemoglobin; MCHC(g/dL), Mean corpuscular
hemoglobin concentration; RDW(%), Red cell distribution width; PLT(K/μL),
Platelets; MPV(fl), Mean platelet volume; NEU(%), Neutrophils; LYO(%),
Lymphocytes; MONO(%), Monocytes; EOS(%), Eosinophils; BASO(%), Basophils.
*Significant difference vs. control, p < 0.05
Table 7 Reticulocyte counts for male and female rats
after 90-day oral administration of silver nanoparticles (n
= 5, EA/1000, mean ± SD)
Dose (mg/Kg)
0 30 125 500
Male 10.00 ± 4.69 8.40 ± 4.72 6.10 ± 2.13 5.80 ± 2.74
Female 12.22 ± 4.84 6.70 ± 3.74* 12.10 ± 5.82 11.90 ± 3.90
*Significant difference vs. control, p < 0.05
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Page 6 of 11are proportional to free silver ions, but it is unclear how
this relates to silver nanoparticles. Absorption of silver
after oral administration has been shown to be subject
to a first-pass effect through the liver, resulting in excre-
tion into the bile [13]. Uncleared silver has been shown
to be deposited in the renal glomerular basement mem-
brane [14-17], mesangium [18], Kupffer cells, and sinu-
soid endothelium cells in the liver [15].
Unlike the 28-day study of Kim et al. [9], the present
study shows intestinal pigmentation and effects from
exposure to silver nanoparticles. Dose-dependent
increases in the silver concentrations in the intestinal
villi, as observed in this and other reports [19], and in
t h eb l o o d ,i n d i c a t et h a tt h eorally absorbed silver from
nanoparticles is able to enter the blood circulation and
be distributed to other organs. Since similar effects have
not been previously reported for soluble silver, there is a
possibility that these effects are due to particles as
opposed to ionized silver.
Increases in renal silver reported in the current study
are consistent with literature showing that ionized silver
is deposited in the renal glomerular basement membrane
[14-17] and mesangium [18]. The gender-related distribu-
tion of silver nanoparticles in the kidneys was also consis-
tent with the results from the 28-day [9], 90-day oral, and
90-day inhalation studies [8]. The average nanoparticle
sizes used in the 28-day and 90-day inhalation experi-
ments were 15 nm and 18-19 nm, respectively, while the
average nanoparticle size used in the 28-day and 90-day
oral toxicity studies was 60 nm and 56 nm, respectively.
Common treatment-related endpoints and distribution
were found in all these studies indicating that distribution
and toxicity do not appear to be dependent on particle
size in the tested range or route of administration.
In previous reports, the target organs for silver nano-
particles were shown to be the liver in a 28-day oral
toxicity study [9] and the liver and lungs in a 90-day
inhalation study [8]. The results of the current study are
consistent with previous reports with respect to the liver
as the target organ and the tissue distribution of silver
originating from nanoparticles. Liver toxicity as evalu-
ated by histopathology included bile-duct hyperplasia
and increased foci, which was consistent with the patho-
logic observations in the 28-day [9] oral toxicity and 90-
day inhalation [8] toxicity studies. Increases in alkaline
phosphatase and cholesterol were also consistent with
the liver toxicity reported by Kim et al. and Sung et al.
In contrast to the 90-day inhalation study, no coagula-
tion effects on peripheral blood were observed. Since
there is similar hepatic pathology in the two studies, it
is not clear whether increased coagulation times were
due to hepatic injury in the inhalation study or some
other mechanism.
Inhaled silver nanoparticles have been shown to
cause lung inflammation [8]. These effects may be due
to particle size since gold nanoparticles (which are not
Figure 3 Coagulation times for male and female rats: A, male prothrombin time (PT); B, male active partial thromboplastine time
(APPT); C, female PT; D, female APPT. (Error bars indicate standard deviation.)
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Page 7 of 11likely to be ionized) show similar effects [20]. Our very
limited data makes it tempting to hypothesize that
effects from silver nanoparticles are not only due to
ionization of silver from the surface of silver nanopar-
ticles, but may originate (at least in part) from direct
effects of nanoparticles. The relationship between par-
ticle effect and effect from ionized silver could be
tested by quantitatively examining target tissues for the
presence of nanoparticles with a concurrent measure-
ment of tissue ionized silver as opposed to measuring
total tissue silver alone. If silver nanoparticles have
particle-related effects which are tissue specific and
significant compared to effects from ionized silver, it
will be important to incorporate such differences into
future occupational ande n v i r o n m e n t a lr i s k
assessments.
Table 8 Histopathological findings for male rats after 90-day oral administration of silver nanoparticles
GROUP Control Low Middle High
Number of animals 10 10 10 10
N % N % N%N%
Liver No microscopic findings 5/10 50 3/10 30 0/10 0 3/10 30
Abnormality 5/10 50 7/10 70 10/10 100 7/10 70
Hyperplasia bile duct minimum 4/10 40 7/10 70 8/10 80 6/10 60
mild 0/10 0 0/10 0 1/10 10 0/10 0
Vacuolation hepatocellular minimum 1/10 10 0/10 0 0/10 0 0/10 0
Necrosis focal minimum 0/10 0 4/10 40 3/10 30 4/10 40
lobular moderate 0/10 0 0/10 0 1/10 10 0/10 0
multifocal moderate 0/10 0 0/10 0 1/10 10 0/10 0
Hemorrhage 0/10 0 0/10 0 1/10 10 0/10 0
Pigmentation 0/10 0 1/10 10 0/10 0 2/10 20
Kidneys No microscopic findings 10/10 100 10/10 100 9/10 90 6/10 60
Abnormality 0/10 0 0/10 0 1/10 10 4/10 40
Basophilia tubular minimum 0/10 0 0/10 0 1/10 10 2/10 20
Inflammation focal minimum 0/10 0 0/10 0 0/10 0 1/10 10
tubular minimum 0/10 0 0/10 0 0/10 0 1/10 10
Lungs No microscopic findings 9/10 90 10/10 100 9/10 90 7/10 70
Abnormality 1/10 10 0/10 0 1/10 10 3/10 30
Inflammation focal minimum 1/10 10 0/10 0 0/10 0 1/10 10
Histocytosis 0/10 0 0/10 0 1/10 10 0/10 0
Mineralization minimum 0/10 0 0/10 0 0/10 0 2/10 20
Anthracosis 0/10 0 0/10 0 0/10 0 1/10 10
Intestines No microscopic findings 10/10 100 10/10 100 2/10 20 2/10 20
Abnormality 0/10 0 0/10 0 8/10 80 8/10 80
Pigment villi yellow 0/10 0 0/10 0 1/10 10 8/10 80
faint yellow 0/10 0 0/10 0 7/10 70 0/10 0
Heart No microscopic findings 10/10 100 10/10 100 8/10 80 8/10 80
Abnormality 0/10 0 0/10 0 2/10 20 2/10 20
Inflammation left ventricle minimum 0/10 0 0/10 0 2/10 20 1/10 10
right ventricle minimum 0/10 0 0/10 0 0/10 0 1/10 10
Eyes No microscopic findings 10/10 100 10/10 100 10/10 100 9/10 90
Abnormality 0/10 0 0/10 0 0/10 0 1/10 10
Inflammation Harderian gland minimum 0/10 0 0/10 0 0/10 0 1/10 10
Pancreas No microscopic findings 10/10 100 10/10 100 10/10 100 8/10 80
Abnormality 0/10 0 0/10 0 0/10 0 2/10 20
Inflammation pancreas minimum 0/10 0 0/10 0 0/10 0 2/10 20
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Page 8 of 11Figure 4 Histopathological findings in liver: (A) control liver, (B) multiple foci of inflammatory cell infiltrates, including eosinophils,
especially around central vein and portal areas (C) bile duct hyperplasia, and (D) several foci of inflammatory cell infiltration,
especially around central vein and sinusoid on hepatic lobules. Bar indicates 100 μm. A. Control (×100). B. High dose (×100). C. High dose
(×100). D. High dose (×200).
Figure 5 Histopathological findings in intestines of male rats dosed with 500 mg/kg silver nanoparticles for 90 days. A. Control male
(×40). B. Control male (×100). C. High-dose male (×40). D. High-dose male (×100).
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Page 9 of 11Table 9 Histopathological findings for female rats after 90-day oral administration of silver nanoparticles
GROUP Control Low Middle High
Number of animals 10 10 10 10
N%N%N%N%
Liver No microscopic findings 5/10 50 2/10 20 2/10 20 3/10 30
Abnormality 5/10 50 8/10 80 8/10 80 7/10 70
Hyperplasia bile duct minimum 3/10 30 7/10 70 8/10 80 7/10 70
Necrosis focal minimum 0/10 0 2/10 20 2/10 20 1/10 10
central vein 0/10 0 0/10 0 0/10 0 1/10 10
Fibrosis minimum 2/10 20 1/10 10 2/10 20 1/10 10
Pigmentation 0/10 0 0/10 0 4/10 40 1/10 10
Kidneys No microscopic findings 5/10 50 2/10 20 3/10 30 1/10 10
Abnormality 5/10 50 8/10 80 7/10 70 9/10 90
Mineralization unilateral minimum 4/10 40 7/10 70 5/10 50 5/10 50
mild 0/10 0 0/10 0 1/10 10 0/10 0
bilateral minimum 1/10 10 1/10 10 1/10 10 4/10 40
Lungs No microscopic findings 10/10 100 10/10 100 9/10 90 10/10 100
Abnormality 0/10 0 0/10 0 1/10 10 0/10 0
Histocytosis 0/10 0 0/10 0 1/10 10 0/10 0
Intestines No microscopic findings 10/10 100 10/10 100 10/10 100 5/10 50
Abnormality 0/10 0 0/10 0 0/10 0 5/10 50
Pigment villi yellow 0/10 0 0/10 0 0/10 0 0/10 0
faint yellow 0/10 0 0/10 0 0/10 0 5/10 50
Eyes No microscopic findings 8/10 80 9/10 90 9/10 90 9/10 90
Abnormality 2/10 20 1/10 10 1/10 10 1/10 10
Inflammation Harderian gland minimum 2/10 20 1/10 10 1/10 10 1/10 0
Pancreas No microscopic findings 10/10 100 10/10 100 10/10 100 9/10 90
Abnormality 0/10 0 0/10 0 0/10 0 1/10 10
Inflammation pancreas minimum 0/10 0 0/10 0 0/10 0 1/10 10
Table 10 Tissue silver content after 90-day oral administration of silver nanoparticles
Silver (μg/g wet weight)
Dose/Sex Testes Liver Kidneys Brain Lungs Blood
0 mg/Kg
Male 0.04 ± 0.02 0.02 ± 0.01 0.04 ± 0.02 0.02 ± 0.01
a 0.10 ± 0.08 0.001 ± 0.000
Female 0.01 ± 0.01 0.03 ± 0.01 0.01 ± 0.01
a 0.05 ± 0.02 0.002 ± 0.002
30 mg/Kg
Male 6.56 ± 0.33** 4.20 ± 1.57**
a 1.49 ± 0.37**
b 0.47 ± 0.18** 1.94 ± 0.64**
b 0.111 ± 0.016**
Female 8.56 ± 3.22**
a 7.98 ± 0.91**
b 0.38 ± 0.05** 4.97 ± 0.90
b 0.087 ± 0.017**
125 mg/Kg
Male 11.84 ± 1.62** 10.19 ± 2.09**
b 8.82 ± 2.13**
b 0.69 ± 0.06** 10.97 ± 3.81** 0.191 ± 0.037**
b
Female 29.13 ± 9.74**
b 37.09 ± 17.44**
b 0.77 ± 0.11** 17.64 ± 9.06** 0.122 ± 0.010**
b
500 mg/Kg
Male 23.75 ± 9.13** 68.65 ± 33.59** 99.19 ± 32.82**
b 3.54 ± 1.44** 56.04 ± 51.14 0.419 ± 0.083**
Female 98.75 ± 31.65** 226.88 ± 55.64**
b 3.70 ± 1.17** 45.83 ± 11.43** 0.303 ± 0.099**
**Significant difference vs. control, p < 0.01. (ANOVA)
a Significant difference vs. distinction of sex, p < 0.05. (T-test)
b Significant difference vs. distinction of sex, p < 0.01. (T-test)
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Page 10 of 11Conclusions
A LOAEL (lowest observable adverse effect level) of 125
mg/kg and a NOAEL (no observable adverse effect
level) of 30 mg/kg are suggested from the current 90-
day oral toxicity study. The LOAEL from this study is
significantly lower than the LOAEL of 300 mg/kg
derived from the 28-day oral toxicity study (Kim et al.,
2008). However, the NOAEL derived from this study is
consistent with the NOAEL of 30 mg/kg derived from
the 28-day oral study (Kim et al., 2008).
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